{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:35:37Z","timestamp":1792676137773,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.mcp.2025.102008","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:35:58Z","timestamp":1737189358000},"page":"102008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Insights into eye genetics and recent advances in ocular gene therapy"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4055-6110","authenticated-orcid":false,"given":"Vikt\u00f3ria","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-3839","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Vars\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-1852","authenticated-orcid":false,"given":"Mirella","family":"Barboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-0122","authenticated-orcid":false,"given":"\u00c1gnes","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Kn\u00e9zy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria Judit","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6246","authenticated-orcid":false,"given":"Bence","family":"Gy\u00f6rgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rivolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcp.2025.102008_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"International human genome sequencing consortium, initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.mcp.2025.102008_bib2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib3","first-page":"190","article-title":"The human genome project","volume":"19","author":"Collins","year":"1995","journal-title":"Alcohol Health Res. World"},{"key":"10.1016\/j.mcp.2025.102008_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature01626","article-title":"A vision for the future of genomics research","volume":"422","author":"Collins","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.mcp.2025.102008_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2015.11.003","article-title":"The sequence of sequencers: the history of sequencing DNA","volume":"107","author":"Heather","year":"2016","journal-title":"Genomics"},{"key":"10.1016\/j.mcp.2025.102008_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41586-023-06490-x","article-title":"The status of the human gene catalogue","volume":"622","author":"Amaral","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.mcp.2025.102008_bib8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1215040","article-title":"A systematic survey of loss-of-function variants in human protein-coding genes","volume":"335","author":"MacArthur","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib9","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41436-018-0414-9","article-title":"Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides","volume":"21","author":"Sangermano","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib10","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.3390\/ijms20205053","article-title":"Prevalence of ABCA4 deep-intronic variants and related phenotype in an unsolved \u201cone-hit\u201d cohort with stargardt disease","volume":"20","author":"Nassisi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mcp.2025.102008_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058657","article-title":"A genome-wide association study for primary open angle glaucoma and macular degeneration reveals novel loci","volume":"8","author":"Scheetz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2025.102008_bib16","article-title":"Practical guide to genetic screening for inherited eye diseases","volume":"12","author":"M\u00e9j\u00e9case","year":"2020","journal-title":"Ther. Adv. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/singaporemedj.SMJ-2022-179","article-title":"Therapeutic landscape for inherited ocular diseases: current and emerging therapies","volume":"64","author":"Chan","year":"2023","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.mcp.2025.102008_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1112270","article-title":"Cost-effective sequence analysis of 113 genes in 1,192 probands with retinitis pigmentosa and Leber congenital amaurosis","volume":"11","author":"Panneman","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mcp.2025.102008_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s13023-021-02145-0","article-title":"Genetic testing and diagnosis of inherited retinal diseases","volume":"16","author":"Lam","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mcp.2025.102008_bib20","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.3390\/jcm13185512","article-title":"Update on clinical trial endpoints in gene therapy trials for inherited retinal diseases","volume":"13","author":"Igoe","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/scientificamerican1174-106","article-title":"Contrast and spatial frequency","volume":"231","author":"Campbell","year":"1974","journal-title":"Sci. Am."},{"key":"10.1016\/j.mcp.2025.102008_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.visres.2013.04.015","article-title":"Measuring contrast sensitivity","volume":"90","author":"Pelli","year":"2013","journal-title":"Vis. Res."},{"key":"10.1016\/j.mcp.2025.102008_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/iovs.61.11.23","article-title":"Dichoptic spatial contrast sensitivity reflects binocular balance in normal and stereoanomalous subjects","volume":"61","author":"Barboni","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/iovs.61.6.40","article-title":"Relationship between acuity and contrast sensitivity: differences due to eye disease","volume":"61","author":"Xiong","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101106","article-title":"Loss-of-function variants in UBAP1L cause autosomal recessive retinal degeneration","volume":"26","author":"Han","year":"2024","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajo.2021.07.018","article-title":"Characterization of retinal function using microperimetry-derived metrics in both adults and children with RPGR-associated retinopathy","volume":"234","author":"Anikina","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/aos.16601","article-title":"Correlations between the Michigan Retinal Degeneration Questionnaire and visual function parameters in patients with retinitis pigmentosa","volume":"102","author":"Karuntu","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/634351","article-title":"Multimodal imaging in hereditary retinal diseases","volume":"2013","author":"Pichi","year":"2013","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3928\/23258160-20160229-01","article-title":"Multimodal imaging in retinal disease: a consensus definition","volume":"47","author":"Novais","year":"2016","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"10.1016\/j.mcp.2025.102008_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.survophthal.2023.11.011","article-title":"Multicolor imaging: current clinical applications","volume":"69","author":"Roy","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.18502\/jovr.v16i3.9439","article-title":"Fundus autofluorescence and clinical applications","volume":"16","author":"Pole","year":"2021","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.mcp.2025.102008_bib32","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3390\/jcm8122078","article-title":"Optical coherence tomography angiography imaging in inherited retinal diseases","volume":"8","author":"Ong","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/JOCO.JOCO_99_20","article-title":"Multimodal imaging in retinitis pigmentosa: correlations among microvascular changes, macular function and retinal structure","volume":"32","author":"Falfoul","year":"2020","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/diagnostics14090878","article-title":"Optical coherence tomography in inherited macular dystrophies: a review","volume":"14","author":"G\u00f3mez-Benlloch","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2025.102008_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/11206721231166434","article-title":"Multimodal imaging in best vitelliform macular dystrophy: literature review and novel insights","volume":"34","author":"Bianco","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1109\/TMI.2022.3222638","article-title":"Ultra-widefield OCT angiography","volume":"42","author":"Niederleithner","year":"2023","journal-title":"IEEE Trans. Med. Imag."},{"key":"10.1016\/j.mcp.2025.102008_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/joco.joco_11_21","article-title":"Retinal vascular abnormalities in different types of inherited retinal dystrophies assessed by optical coherence tomography angiography","volume":"33","author":"Sabbaghi","year":"2021","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2474126420951988","article-title":"Peripheral leakage on ultra-widefield fluorescein angiography in patients with inherited retinal degeneration","volume":"5","author":"Park","year":"2020","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.mcp.2025.102008_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101244","volume":"100","author":"Georgiou","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mcp.2025.102008_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2011.09.029","article-title":"Eye development genes and known syndromes","volume":"104","author":"Slavotinek","year":"2011","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.mcp.2025.102008_bib41","doi-asserted-by":"crossref","DOI":"10.1007\/s10633-022-09872-0","article-title":"ISCEV Standard for full-field clinical electroretinography (2022 update)","author":"Robson","year":"2022","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10633-021-09853-9","article-title":"Effects of fixed cutoff filtering on dark- and light-adapted ERG components and the application of variable cutoff filter","volume":"144","author":"Gao","year":"2022","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10633-018-9638-x","article-title":"ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram","volume":"136","author":"Frishman","year":"2018","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100861","article-title":"Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations","volume":"79","author":"Cremers","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mcp.2025.102008_bib45","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1167\/iovs.09-3611","article-title":"The natural history of stargardt disease with specific sequence mutation in the ABCA4 gene","volume":"50","author":"Genead","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib46","doi-asserted-by":"crossref","DOI":"10.1007\/s10633-020-09812-w","article-title":"ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update)","author":"Hoffmann","year":"2021","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10633-024-09970-1","article-title":"ISCEV standard for clinical pattern electroretinography (2024 update)","volume":"148","author":"Thompson","year":"2024","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.11.3.31","article-title":"The relationship between stage of Leber's hereditary optic neuropathy and pattern electroretinogram latency","volume":"11","author":"Porciatti","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.mcp.2025.102008_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","article-title":"International Society for Clinical Electrophysiology of Vision, ISCEV standard for clinical visual evoked potentials: (2016 update)","volume":"133","author":"Odom","year":"2016","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10633-024-09968-9","article-title":"Electroretinographic oscillatory potentials in Leber hereditary optic neuropathy","volume":"148","author":"Barboni","year":"2024","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1167\/iovs.09-3899","article-title":"Flicker ERGs representing chromaticity and luminance signals","volume":"51","author":"Kremers","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib52","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1167\/iovs.16-19287","article-title":"Dystrophin is required for proper functioning of luminance and red-green cone opponent mechanisms in the human retina","volume":"57","author":"Barboni","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib53","doi-asserted-by":"crossref","first-page":"B92","DOI":"10.1364\/JOSAA.35.000B92","article-title":"Electroretinographical determination of human color vision type","volume":"35","author":"Aher","year":"2018","journal-title":"J. Opt. Soc. Am. Opt Image Sci. Vis."},{"key":"10.1016\/j.mcp.2025.102008_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.65.8.6","article-title":"Pupillary light reflex reveals melanopsin system alteration in the background of myopia-26, the female limited form of early-onset high myopia","volume":"65","author":"Barboni","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-017-9573-2","article-title":"International society for Clinical Electrophysiology of Vision, ISCEV standard for clinical electro-oculography (2017 update)","volume":"134","author":"Constable","year":"2017","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.preteyeres.2005.11.001","article-title":"The electro-oculogram","volume":"25","author":"Arden","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mcp.2025.102008_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1399-0004.2001.600501.x","article-title":"Goals of genetic counseling","volume":"60","author":"Biesecker","year":"2001","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","article-title":"A new definition of genetic counseling: national society of genetic counselors' task force report","volume":"15","author":"Resta","year":"2006","journal-title":"J. Genet. Counsel."},{"key":"10.1016\/j.mcp.2025.102008_bib59","unstructured":"ACMG Practice Guideline, Genet. Med. (2021). ISSN 1530-0366 (online) ISSN 1098-3600 (print)https:\/\/www.nature.com\/gim\/articles?type=acmg-practice-guidelines. (Accessed 30 November 2024)."},{"key":"10.1016\/j.mcp.2025.102008_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/bmb\/ldy008","article-title":"Genetic counselling in the era of genomic medicine","volume":"126","author":"Patch","year":"2018","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.mcp.2025.102008_bib61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/13816810.2020.1804943","article-title":"Inherited retinal degeneration current genetics practices - a needs assessment","volume":"41","author":"Strait","year":"2020","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib62","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.3390\/ijms24087481","article-title":"Retinitis pigmentosa: current clinical management and emerging therapies","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/srep13187","article-title":"Whole exome sequencing reveals mutations in known retinal disease genes in 33 out of 68 Israeli families with inherited retinopathies","volume":"5","author":"Beryozkin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcp.2025.102008_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajhg.2016.12.003","article-title":"Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease","volume":"100","author":"Carss","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.645600","article-title":"Updating the genetic landscape of inherited retinal dystrophies","volume":"9","author":"Garc\u00eda Boh\u00f3rquez","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mcp.2025.102008_bib66","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcp.2025.102008_bib67","first-page":"4664","article-title":"Exome and genome sequencing after inconclusive targeted gene panel testing increases diagnostic yield in patients with inherited retinal disease","volume":"65","author":"Darr","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ejhg.2013.72","article-title":"Panel-based next generation sequencing as a reliable and efficient technique to detect mutations in unselected patients with retinal dystrophies","volume":"22","author":"Gl\u00f6ckle","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib69","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1093\/hmg\/ddx185","article-title":"Toward an elucidation of the molecular genetics of inherited retinal degenerations","volume":"26","author":"Farrar","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(75)90213-2","article-title":"A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase","volume":"94","author":"Sanger","year":"1975","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.mcp.2025.102008_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mcp.2025.102008_bib77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/13816810.2019.1675178","article-title":"Next-generation sequencing and its application in diagnosis of retinitis pigmentosa","volume":"40","author":"Salmaninejad","year":"2019","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib78","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/humu.22332","article-title":"Targeted next-generation sequencing can replace sanger sequencing in clinical diagnostics","volume":"34","author":"Sikkema-Raddatz","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mcp.2025.102008_bib79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-7-8","article-title":"Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases","volume":"7","author":"Audo","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mcp.2025.102008_bib80","doi-asserted-by":"crossref","DOI":"10.21037\/tp.2020.03.06","article-title":"The third-generation sequencing: the advanced approach to genetic diseases","volume":"9","author":"Xiao","year":"2020","journal-title":"Transl. Pediatr."},{"key":"10.1016\/j.mcp.2025.102008_bib81","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcp.2025.102008_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mcp.2025.102008_bib83","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.bbamcr.2017.04.017","article-title":"Transdifferentiation and reprogramming: overview of the processes, their similarities and differences","volume":"1864","author":"Cie\u015blar-Pobuda","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.mcp.2025.102008_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mcp.2025.102008_bib85","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hgtb.2016.086","article-title":"Evaluation of an optimized injection system for retinal gene therapy in human patients","volume":"27","author":"Fischer","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.mcp.2025.102008_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000526317","article-title":"Gene therapy for inherited retinal disease: long-term durability of effect","volume":"66","author":"Leroy","year":"2023","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.mcp.2025.102008_bib87","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations","volume":"86","author":"Botto","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.mcp.2025.102008_bib89","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib90","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.3390\/ijms22094534","article-title":"An update on gene therapy for inherited retinal dystrophy: experience in leber congenital amaurosis clinical trials","volume":"22","author":"Chiu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib91","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/3813","article-title":"Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle","volume":"20","author":"Redmond","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib92","doi-asserted-by":"crossref","first-page":"15751","DOI":"10.1016\/S0021-9258(18)82319-5","article-title":"Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro","volume":"268","author":"Hamel","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcp.2025.102008_bib93","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ng1097-194","article-title":"Mutations in RPE65 cause autosomal recessive childhood\u2013onset severe retinal dystrophy","volume":"17","author":"Gu","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib94","first-page":"4293","article-title":"Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration","volume":"41","author":"Thompson","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib95","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","article-title":"Visual acuity, retinal morphology, and patients' perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease","volume":"6","author":"Sengillo","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.mcp.2025.102008_bib97","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2020-318286","article-title":"Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec","volume":"106","author":"Stingl","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib98","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"PERCEIVE study group, real-world safety and effectiveness of voretigene neparvovec: results up to 2 Years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.mcp.2025.102008_bib99","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy following subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.mcp.2025.102008_bib100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.2.13","article-title":"Chorioretinal atrophy growth after voretigene neparvovec retinotopically is connected to retinal functional rescue","volume":"13","author":"Stingl","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.mcp.2025.102008_bib101","first-page":"42","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Oph. Retina"},{"key":"10.1016\/j.mcp.2025.102008_bib102","article-title":"Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?","volume":"10","author":"Dormegny","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.mcp.2025.102008_bib104","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0140-6736(24)01447-8","article-title":"Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1\/2, multicentre, open-label, unilateral dose escalation study","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.mcp.2025.102008_bib105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Retinal gene therapy in X-linked retinitis pigmentosa caused by mutations in RPGR: results at 6 months in a first in human clinical trial","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib106","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","article-title":"Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2\/3 study","volume":"131","author":"Lam","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib107","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2023.05.009","article-title":"First-in-Human gene therapy trial of AAV8-hCARp.hCNGB3 in adults and children with CNGB3-associated achromatopsia","volume":"253","author":"Michaelides","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib108","unstructured":"Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia | Biogen, (n.d.). https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-topline-results-phase-3-gene-therapy-study (accessed December 9, 2024)."},{"key":"10.1016\/j.mcp.2025.102008_bib109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/IIO.0000000000000385","article-title":"Choroideremia gene therapy","volume":"61","author":"Lam","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.mcp.2025.102008_bib110","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/bjophthalmol-2021-319067","article-title":"Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial","volume":"106","author":"Reichel","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.mcp.2025.102008_bib111","first-page":"6083","article-title":"Ocular post-mortem analyses with histopathological and molecular assessments in LHON following AAV2 gene therapy","volume":"65","author":"Carelli","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib112","first-page":"1395","article-title":"Joint effects of polymorphisms in the HTRA1, LOC387715\/ARMS2, and CFH genes on AMD in a Caucasian population","volume":"14","author":"Francis","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.mcp.2025.102008_bib113","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/hmg\/ddr270","article-title":"Common variants near FRK\/COL10A1 and VEGFA are associated with advanced age-related macular degeneration","volume":"20","author":"Yu","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcp.2025.102008_bib114","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.ophtha.2012.06.042","article-title":"Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management","volume":"119","author":"Priya","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ophtha.2012.10.006","article-title":"Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration","volume":"120","author":"Abedi","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib116","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ophtha.2014.07.049","article-title":"Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the age-related eye disease study","volume":"122","author":"Awh","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib117","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1718059115","article-title":"CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation","volume":"115","author":"Vavvas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mcp.2025.102008_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297135","article-title":"Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients","volume":"19","author":"Sorenson","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2025.102008_bib119","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.mcp.2025.102008_bib120","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.mcp.2025.102008_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.mcp.2025.102008_bib122","unstructured":"ASRS, Adverum Biotechnologies presenting positive Ixo-vec clinical data from the 26-week interim analysis of the LUNA Phase 2 trial, Ophthalmol. Times (2024) https:\/\/www.ophthalmologytimes.com\/view\/asrs-2024-adverum-biotechnologies-presenting-positive-ixo-vec-clinical-data-from-the-26-week-interim-analysis-of-the-luna-phase-2-trial. (Accessed 12 December 2024)."},{"key":"10.1016\/j.mcp.2025.102008_bib123","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.stemcr.2022.08.005","article-title":"Investigation of PTC124-mediated translational readthrough in a retinal organoid model of AIPL1-associated Leber congenital amaurosis","volume":"17","author":"Leung","year":"2022","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.mcp.2025.102008_bib124","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3390\/ijms23073541","article-title":"Translational read-through drugs (TRIDs) are able to restore protein expression and ciliogenesis in fibroblasts of patients with retinitis pigmentosa caused by a premature termination codon in FAM161A","volume":"23","author":"Beryozkin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib125","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.mcp.2025.102008_bib126","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41591-019-0346-1","article-title":"Gene therapy for retinal dystrophy","volume":"25","author":"Sahel","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib130","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib131","unstructured":"www.editasmedicine.com, (accessed December 8, 2024)."},{"key":"10.1016\/j.mcp.2025.102008_bib132","author":"Muller"},{"key":"10.1016\/j.mcp.2025.102008_bib133","first-page":"3786","article-title":"Adenine-base editing corrects the most common ABCA4 mutation causing stargardt disease","volume":"64","author":"Gy\u00f6rgy","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib134","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-01234-1","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mcp.2025.102008_bib135","unstructured":"Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases - Prime Medicine, Inc., (n.d.). https:\/\/investors.primemedicine.com\/news-releases\/news-release-details\/prime-medicine-presents-first-vivo-proof-concept-prime-editing\/(accessed December 8, 2024)."},{"key":"10.1016\/j.mcp.2025.102008_bib136","series-title":"Prime Medicine Presents First in Vivo Proof-Of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases","author":"Inc","year":"2023"},{"key":"10.1016\/j.mcp.2025.102008_bib137","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ymthe.2020.08.012","article-title":"Therapy in rhodopsin-mediated autosomal dominant retinitis pigmentosa","volume":"28","author":"Meng","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mcp.2025.102008_bib138","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3390\/jcm13144224","article-title":"Optogenetics and targeted gene therapy for retinal diseases: unravelling the fundamentals, applications, and future perspectives","volume":"13","author":"Kulbay","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib139","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","article-title":"Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases","volume":"29","author":"Xue","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.mcp.2025.102008_bib141","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/IAE.0000000000003133","article-title":"Leber congenital amaurosis due to CEP290 mutations-severe vision impairment with a high unmet medical need: a Review","volume":"41","author":"Leroy","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.mcp.2025.102008_bib142","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1167\/iovs.15-16400","article-title":"Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration","volume":"56","author":"Murray","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib143","doi-asserted-by":"crossref","first-page":"E8547","DOI":"10.1073\/pnas.1805055115","article-title":"Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector","volume":"115","author":"Cideciyan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mcp.2025.102008_bib145","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jcyt.2024.03.037","article-title":"Safety and efficacy results from a phase 1\/2 clinical trial of ocu400 modifier gene therapy for treatment of retinitis pigmentosa","volume":"26","author":"Upadhyay","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.mcp.2025.102008_bib146","first-page":"406","article-title":"OCU400 nuclear hormone receptor-based gene modifier therapy: safety and efficacy from phase 1\/2 clinical trial for retinitis pigmentosa associated with NR2E3 and RHO mutations","volume":"65","author":"Lam","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib147","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nn.2117","article-title":"Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration","volume":"11","author":"Lagali","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.mcp.2025.102008_bib148","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.1190897","article-title":"Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa","volume":"329","author":"Busskamp","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib149","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/mt.2011.69","article-title":"Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness","volume":"19","author":"Doroudchi","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mcp.2025.102008_bib150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.omtm.2023.05.005","article-title":"A clinically viable approach to restoring visual function using optogenetic gene therapy","volume":"29","author":"Yan","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mcp.2025.102008_bib152","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib153","first-page":"5443","article-title":"Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: a phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)","volume":"64","author":"Boyer","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib154","first-page":"3546","article-title":"MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial","volume":"64","author":"Gonzalez","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib155","series-title":"Nanoscope Therapeutics Announces Positive Top-Line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa","author":"Therapeutics","year":"2024"},{"key":"10.1016\/j.mcp.2025.102008_bib156","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ophtha.2019.03.019","article-title":"Assessing \u201ccell therapy\u201d clinics offering treatments of ocular conditions using direct-to-consumer marketing websites in the United States","volume":"126","author":"Nirwan","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcp.2025.102008_bib157","doi-asserted-by":"crossref","unstructured":"S. Sen, T.A.C. de Guimaraes, A.G. Filho, L. Fabozzi, R.A. Pearson, M. Michaelides, Stem cell-based therapies for retinal diseases: focus on clinical trials and future prospects, Ophthalmic Genet. (n.d.) 1\u201314. https:\/\/doi.org\/10.1080\/13816810.2024.2423784.","DOI":"10.1080\/13816810.2024.2423784"},{"key":"10.1016\/j.mcp.2025.102008_bib158","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMoa1609583","article-title":"Vision loss after intravitreal injection of autologous \u201cstem cells\u201d for AMD","volume":"376","author":"Kuriyan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100779","article-title":"Retinal stem cell transplantation: balancing safety and potential","volume":"75","author":"Singh","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"issue":"7","key":"10.1016\/j.mcp.2025.102008_bib160","article-title":"CRISPR -Cas9-mediated gene correction in inducedpluripotent stem cells derived from oculocutaneous albinism type2 patients rescues pigmentation defect in retinal pigment epithe-lium","volume":"63","author":"Leigh","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.mcp.2025.102008_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109022","article-title":"Restoration of visual function in advanced disease after transplantation of purified human pluripotent stem cell-derived cone photoreceptors","volume":"35","author":"Ribeiro","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcp.2025.102008_bib162","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.stemcr.2016.08.010","article-title":"Successful transplantation of retinal pigment epithelial cells from MHC homozygote iPSCs in MHC-matched models","volume":"7","author":"Sugita","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.mcp.2025.102008_bib163","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.stemcr.2016.12.008","article-title":"iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice","volume":"8","author":"Mandai","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.mcp.2025.102008_bib164","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00109-020-01960-5","article-title":"Stem cell therapies for retinal diseases: from bench to bedside","volume":"98","author":"Shen","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.mcp.2025.102008_bib165","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1126\/science.1067996","article-title":"Will retinal implants restore vision?","volume":"295","author":"Zrenner","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mcp.2025.102008_bib166","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/17434440.2014.862494","article-title":"The functional performance of the Argus II retinal prosthesis","volume":"11","author":"Stronks","year":"2014","journal-title":"Expet Rev. Med. Dev."},{"key":"10.1016\/j.mcp.2025.102008_bib167","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/eye.2016.280","article-title":"Electronic retinal implant surgery","volume":"31","author":"MacLaren","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.mcp.2025.102008_bib168","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.clinph.2019.11.029","article-title":"An update on retinal prostheses","volume":"131","author":"Ayton","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.mcp.2025.102008_bib169","doi-asserted-by":"crossref","DOI":"10.2196\/17436","article-title":"Effects of the argus II retinal prosthesis system on the quality of life of patients with ultra-low vision due to retinitis pigmentosa: protocol for a single-arm, mixed methods study","volume":"10","author":"White","year":"2021","journal-title":"JMIR Res. Protoc."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850825000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850825000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:56:06Z","timestamp":1740369366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850825000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":165,"alternative-id":["S0890850825000015"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2025.102008","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into eye genetics and recent advances in ocular gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2025.102008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102008"}}